Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications by Danielle Medeiros | Sep 23, 2020Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide by Danielle Medeiros | Sep 9, 2019EpiVax_PANDA_Taspoglutide_April_19_Final
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS by Kathleen Gonzalez | Oct 30, 2018EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release
